Keywords: Osiris, Prochymal, Stem cell therapy, Graft-vs-host-disease, New Zealand
Osiris gets second approval for Prochymal, in New Zealand
Article | 15 June 2012
USA-based Osiris Therapeutics (Nasdaq: OSIR) has received a second approval to market its first-in-class stem cell therapy Prochymal (remestemcel-L), for ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
